Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime: The dose matters, too

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 915-916

  Altshuler, Jerry ^a   Aitken, Samuel L ^b,c   Guervil, David ^a   Esaian, Diana ^d   Papadopoulos, John ^d   Arias, Cesar A ^e  

^a EAST TEXAS MEDICAL CENTER   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC THERAPY; BACTEREMIA; DRUG TARGETING; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENOTYPE; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE;

EID: 84883242242     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit383     Document Type: Letter

References (5)

1. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepimesusceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488-95.
2. Dudley MN, Ambrose PG, Bhavnani SM. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. cephalosporins and aztreonam. Clin Infect Dis 2013; 56:1301-9.
3. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11(suppl 6):10-7.
4. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic- pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006; 58:987-93.
5. Bhat SV, Peleg AY, Lodise TP, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007; 51:4390-5.